Sign In
Buy RXRX
$3.52
+0.180 (+5.39%)
At Close: Jun 26, 2026
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?
11:06am, Wednesday, 23'rd Jul 2025
Recursion Pharmaceuticals bets on REC-4881, cancer candidates and new hypophosphatasia therapy to rebuild momentum after key drug cuts rattled investors.
Recursion Pharmaceuticals (RXRX) Soars 5.8%: Is Further Upside Left in the Stock?
11:15am, Monday, 21'st Jul 2025
Recursion Pharmaceuticals (RXRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further
Recursion Pharmaceuticals (RXRX) Rises Higher Than Market: Key Facts
06:50pm, Thursday, 17'th Jul 2025
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $5.52, indicating a +2.41% shift from the previous trading day.
Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock
12:31pm, Thursday, 17'th Jul 2025
RXRX gains 5.5% in a month on positive pipeline update; long-term hold advised given strong potential of its AI-driven drug discovery platform.
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
11:01am, Wednesday, 16'th Jul 2025
RXRX is scaling its AI-driven drug discovery technology through billion-dollar pharma deals and strategic tech alliances.
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing
06:51pm, Thursday, 10'th Jul 2025
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.72, marking a +2.24% move from the previous day.
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program
01:01pm, Wednesday, 09'th Jul 2025
Recursion Pharmaceuticals stock jumps after securing full rights to REV102, aiming to fast-track the first oral therapy for hypophosphatasia.
10 Under-the-Radar Tech Stocks With Incredible Growth Potential
04:23am, Wednesday, 09'th Jul 2025
It's not exactly a secret that big technology stocks like Microsoft, Nvidia, and Alphabet have led the market for several years now. And rightfully so.
Here's Why Shares in Recursion Pharmaceuticals Surged Today
01:28pm, Tuesday, 08'th Jul 2025
Shares in biotech company Recursion Pharmaceuticals (RXRX 10.65%) surged by more than 12% by 11 a.m. ET today. The move is due to a de-risking event in its drug discovery pipeline.
What's Happening With RXRX Stock?
07:10am, Tuesday, 08'th Jul 2025
Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this underp
The Hottest 10 Artificial Intelligence (AI) Stocks on the Market
06:00am, Tuesday, 08'th Jul 2025
There's little doubt that artificial intelligence is here to stay. It's just too game-changing to put back in the box now.
Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith?
11:26am, Monday, 07'th Jul 2025
Recursion Pharmaceuticals axes three drug programs after weak study data, but shifts focus to more promising candidates like REC-4881 to regain ground.
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today
06:51pm, Thursday, 03'rd Jul 2025
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $5.27, denoting a +1.15% move from the preceding trading day.
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process?
11:30am, Wednesday, 02'nd Jul 2025
Recursion Pharmaceuticals is transforming drug discovery with AI-driven RecursionOS, slashing costs and boosting development speed.
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note
06:51pm, Friday, 27'th Jun 2025
Recursion Pharmaceuticals (RXRX) reached $5.03 at the closing of the latest trading day, reflecting a -6.85% change compared to its last close.
